NEW YORK (Reuters) - Amylin Pharmaceuticals Inc , which spurned a $3.5 billion takeover bid from Bristol-Meyers Squibb Co and is fending off activist investor Carl Icahn, is exploring a sale, sources familiar with the situation said on Sunday.
AMYLIN (AMLN.NQ)has hired Credit Suisse
The company, which makes the diabetes drugs Byetta and Bydureon, started reaching out to potential buyers last week, according to these sources.
Amylin and Goldman declined to comment, while the other advisers were not immediately available for comment.
(Reporting by Paritosh Bansal and Soyoung Kim; Editing by Dale Hudson)
